Amgen and KAI Pharmaceuticals announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company. Amgen will pay $315 million in cash to acquire KAI. Following the completion of the transaction, KAI will become a wholly owned subsidiary of Amgen.
KAI’s lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. KAI-4169 is an innovative experimental therapy that is administered intravenously at the same time the patient is undergoing dialysis. The vast majority of CKD patients on dialysis are affected by SHPT, a component of chronic kidney disease bone disorder (CKD-MBD), which can lead to serious consequences.
Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to closing.